Rheumatology

Host: Richard Johnson, MD

Guest: John K. Botson, MD, RPh

This activity is no longer available for continuing education credit.

Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

Host: Richard Johnson, MD

Guest: John K. Botson, MD, RPh

This activity is no longer available for continuing education credit.

Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

Host: Richard Johnson, MD

Guest: Brittany Weber, MD, PhD

This activity is no longer available for continuing education credit.

Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

Guest: Robert A. Baldor, MD

Guest: Chadwick R. Johr, MD

This innovative, 45-minute, case-based CME activity features two prominent faculty covering important, timely issues and data related to the detection of autoimmune (AI) disorders. Using case studies, the faculty will explore diagnosis and management strategies to maximize patient care. In addition to the analysis of AI cases, key topics will be covered, including:

• Evaluation for suspected RA
• Combination serological assessment
• 14-3-3eta as a marker for joint damage
• Autoantibodies in SLE diagnosis and classification
• ANA IFA and subserologies
• Diagnosis of RA, Sjögren’s, Lupus, and Systemic Sclerosis

Guest: Robert A. Baldor, MD

Guest: Chadwick R. Johr, MD

This innovative, 30-minute, online activity features a Video Expert Dialogue with two prominent faculty covering important, timely issues and data related to the detection of autoimmune (AI) disorders. The emphasis is on the unique role primary care providers play in diagnosing and managing AI and maximizing patient care. Topics include:

• Overview of connective tissue diseases and ANA testing
• ANA IFA and ELISA
• New tests
• Subserologies with IFA
• Choosing wisely about ANA testing
• Diagnosis of RA, Sjögren’s, Lupus, and Systemic Sclerosis
• Titer Information
• Negative ANA testing
• When to refer

We’ll be discussing autoantibody testing for autoimmune diseases, or more precisely, connective tissue diseases. Our purpose here is to discuss how autoantibody testing, such as the ANA, may be used in the primary care setting to diagnose these disorders. Using the ANA test combined with a good medical exam and a good history, along with signs and symptoms of connective tissue diseases, will help to achieve greater benefits in diagnosing and treating patients.

Guest: Leonard H. Calabrese, DO

Guest: John R. Tesser, MD

This activity provides patient and practice-specific biosimilars content for clinicians in rheumatology practice.